The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

The last time I drove a car on the public road was a year ago yesterday, on my way home from the MOT in Ballymena. To ...

UBlock Origin, Just Read, and Toby are among the essential free extensions every user should add to their browser for a ...

Veteran investors have plunked down a combined $70.8 million in separate deals to buy big industrial hubs in the East Bay.

Veteran investors have plunked down a combined $70.8 million in separate deals to buy big industrial hubs in the East Bay.

The epilogue of Homeland first gives the impression that Carrie has been turned into a Russian propagandist altogether. She ...

Gateway Center, the three-building complex with 129,000 square feet at the corner of East Speedway and North Kolb Road, ...